A pathology-supported genetic testing algorithm incorporating point-of-care BRCA1/2 testing is used to help determine the need for whole exome/genome sequencing in patients diagnosed or with a family history of cancer. Read More. In addition, genes and lifestyle/environmental factors involved in all the major NCD pathways are evaluated as previously described in relation to hypercholesterolaemia, homocysteine accumulation, blood clotting, iron overload/deficiency and drug metabolism. Read More.